Nivolumab vs Atezolizumab
## Overview
Nivolumab (anti-PD-1, IgG4) and atezolizumab (anti-PD-L1, IgG1) represent different targets in the PD-1/PD-L1 pathway. Nivolumab has broader direct approval including extensive combination with ipilimumab; atezolizumab has a specific HCC indication (with bevacizumab) and SCLC combination.
## Mechanism of Action
Nivolumab blocks PD-1 receptor. Atezolizumab blocks PD-L1 (preserving PD-L2 signaling). The Fc of atezolizumab is engineered to prevent ADCC; nivolumab's IgG4 also has minimal ADCC.
## Key Indication Differences
Nivolumab's unique niche: combination with ipilimumab across multiple tumor types (melanoma, NSCLC, RCC, mesothelioma, colorectal MSI-H, esophageal/GEJ). Atezolizumab's unique niche: HCC + bevacizumab (IMbrave150) as preferred first-line over sorafenib.
## Clinical Evidence
Both have extensive pivotal trials. Key head-to-head data is sparse — most comparisons are cross-trial. In NSCLC, indirect comparisons suggest similar efficacy of anti-PD-1 vs. anti-PD-L1 agents.
## Key Takeaways
- Nivolumab: dual checkpoint (nivo+ipi) unique combinations
- Atezolizumab: HCC standard of care (with bevacizumab); SCLC (IMPOWER133)
- Both anti-PD-(L)1 agents with comparable irAE profiles
Fazit
Nivolumab is the preferred agent when dual checkpoint blockade with ipilimumab is indicated. Atezolizumab is preferred for HCC first-line (with bevacizumab) and SCLC combination therapy. Both are appropriate depending on the specific tumor type and regimen context.